Depleting CAR T cells after tumor treatment reverses B cell deficiency in mice

Genetically engineered T cells, or CAR T cells, represent a promising approach to treat multiple types of cancer. These therapies can eliminate tumors by targeting specific markers that are expressed on different cancer cell types. CAR T cell treatments for B cell-associated cancers have been particularly successful in eradicating tumors. These treatments destroy tumor cells expressing CD19, a protein that is upregulated at the early stages of B cell development. Unfortunately, because CAR T cells persist after a patient goes into remission, continual targeting of CD19 can lead to long-term depletion of healthy B cells.

In this issue of the JCI, a team led by Dirk Busch at Technical University München has developed a strategy to prevent depletion of healthy B cells after successful CAR T cell treatments for B cell lymphomas.

They created CD19-targeting CAR T cells that also express a non-functional form of another protein called EGFR. They then treated a of leukemia with the EGFR- and CD19-targeting T cells.

After the treatment successfully eliminated B cell tumors in these mice, the researchers administered an antibody for EGFR, which depleted CAR T cells.

This strategy permanently restored levels of healthy B cells without causing cancer relapse in the mouse model.

This work provides evidence that incorporating an additional targeting mechanism into genetically engineered cells may improve the safety of these cell-based therapies.

More information: Paulina J. Paszkiewicz et al, Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI84813

Provided by JCI Journals
Citation: Depleting CAR T cells after tumor treatment reverses B cell deficiency in mice (2016, October 17) retrieved 16 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers engineer 'micro-pharmacies' in CAR T cells to treat B cell lymphomas


Feedback to editors